[1
]
Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City,
UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;
Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas
Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research
Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston,
TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman, Winship
Cancer Institute, Emory University School of Medicine, Atlanta, GA; Lynn E. Spitler,
Northern California Melanoma Center, San Francisco; Gregory A. Daniels, University
of California San Diego Medical Center, Moores Cancer Center, La Jolla; Yining Ye,
Bin Yao, Ai Li, Ari Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA;
Igor Puzanov, Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's
University Hospital and Health Network, Bethlehem, and Temple University School of
Medicine, Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics,
Iowa City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle
A. Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado Cancer
Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; Jonathan
S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, Washington University
School of Medicine, St Louis, MO; Kevin Harrington, Institute of Cancer Research,
Royal Marsden Hospital, London; Mark R. Middleton, National Institute for Health Research
Biomedical Research Centre, Oxford, United Kingdom; Wilson H. Miller Jr, McGill University,
Montreal, Quebec, Canada; and Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
[2
]
Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City,
UT; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;
Frances Collichio, University of North Carolina Medical Center, Chapel Hill, NC; Thomas
Amatruda, Minnesota Oncology, Fridley, MN; Neil Senzer, Mary Crowley Cancer Research
Center, Dallas; Merrick Ross, University of Texas MD Anderson Cancer Center, Houston,
TX; Jason Chesney, University of Louisville, Louisville, KY; Keith A. Delman, Winship
Cancer Institute, Emory University School of Medicine, Atlanta, GA; Lynn E. Spitler,
Northern California Melanoma Center, San Francisco; Gregory A. Daniels, University
of California San Diego Medical Center, Moores Cancer Center, La Jolla; Yining Ye,
Bin Yao, Ai Li, Ari Vander Walde, and Jennifer Gansert, Amgen, Thousand Oaks, CA;
Igor Puzanov, Vanderbilt University, Nashville, TN; Sanjiv S. Agarwala, St Luke's
University Hospital and Health Network, Bethlehem, and Temple University School of
Medicine, Philadelphia, PA; Mohammed Milhem, University of Iowa Hospitals and Clinics,
Iowa City, IA; Lee Cranmer, University of Arizona, Tucson, AZ; Brendan Curti, Earle
A. Chiles Research Institute, Portland, OR; Karl Lewis, University of Colorado Cancer
Center, Aurora, CO; Troy Guthrie, Baptist Cancer Institute, Jacksonville; Jonathan
S. Zager, Moffitt Cancer Center, Tampa, FL; Gerald P. Linette, Washington University
School of Medicine, St Louis, MO; Kevin Harrington, Institute of Cancer Research,
Royal Marsden Hospital, London; Mark R. Middleton, National Institute for Health Research
Biomedical Research Centre, Oxford, United Kingdom; Wilson H. Miller Jr, McGill University,
Montreal, Quebec, Canada; and Susan Doleman and Robert S. Coffin, Amgen, Woburn, MA.
howard.kaufman@rutgers.edu.